These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 26141219)
1. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations. Gong L; Xiong M; Huang Z; Miao L; Fan Y Lung Cancer; 2015 Sep; 89(3):268-73. PubMed ID: 26141219 [TBL] [Abstract][Full Text] [Related]
2. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613 [TBL] [Abstract][Full Text] [Related]
4. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes. Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808 [TBL] [Abstract][Full Text] [Related]
5. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822 [TBL] [Abstract][Full Text] [Related]
6. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer. Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302 [TBL] [Abstract][Full Text] [Related]
7. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China. Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645 [TBL] [Abstract][Full Text] [Related]
9. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628 [TBL] [Abstract][Full Text] [Related]
11. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer. Fan Y; Huang Z; Fang L; Miao L; Gong L; Yu H; Yang H; Lei T; Mao W Cancer Chemother Pharmacol; 2015 Sep; 76(3):517-23. PubMed ID: 26148750 [TBL] [Abstract][Full Text] [Related]
13. Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases. Fan Y; Xu Y; Gong L; Fang L; Lu H; Qin J; Han N; Xie F; Qiu G; Huang Z Sci Rep; 2017 Mar; 7():45193. PubMed ID: 28332624 [TBL] [Abstract][Full Text] [Related]
14. [Clinical Analysis of Icotinib on Beneficiary of Advanced Non-small Cell Lung Cancer with EGFR Common Mutation]. Jiang X; Wang W; Zhang Y Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):200-6. PubMed ID: 27118647 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lu S; Ye M; Ding L; Tan F; Fu J; Wu B Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283 [TBL] [Abstract][Full Text] [Related]
16. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations. Yao S; Zhi X; Wang R; Qian K; Hu M; Zhang Y Thorac Cancer; 2016 Sep; 7(5):543-548. PubMed ID: 27766784 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer. Liu D; Zhang L; Wu Y; Jiang J; Tan F; Wang Y; Liu Y; Hu P Lung Cancer; 2015 Sep; 89(3):262-7. PubMed ID: 26162563 [TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis. Qu J; Wang YN; Xu P; Xiang DX; Yang R; Wei W; Qu Q Oncotarget; 2017 May; 8(20):33961-33971. PubMed ID: 28430623 [TBL] [Abstract][Full Text] [Related]
19. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Masuda T; Hattori N; Hamada A; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Kohno N Cancer Chemother Pharmacol; 2011 Jun; 67(6):1465-9. PubMed ID: 21274533 [TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. Liao BC; Lee JH; Lin CC; Chen YF; Chang CH; Ho CC; Shih JY; Yu CJ; Yang JC J Thorac Oncol; 2015 Dec; 10(12):1754-61. PubMed ID: 26334749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]